We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$35.9M
Cap. Flow %
-2.87%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Consumer Discretionary 0.07%
3 Financials 0.04%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAPR icon
151
Capricor Therapeutics
CAPR
$380M
$16K ﹤0.01%
400
– –
NUVA
152
DELISTED
NuVasive, Inc.
NUVA
$12K ﹤0.01%
+252
New +$13K
XBI icon
153
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$6K ﹤0.01%
+100
New +$7.88K
ACGN
154
DELISTED
Aceragen Inc
ACGN
$5K ﹤0.01%
+11
New +$4.86K
HSTO
155
DELISTED
Histogen Inc. Common Stock
HSTO
$2K ﹤0.01%
2
-498
-100% -$454K
ASND icon
156
Ascendis Pharma A/S
ASND
$16.5B
– –
-10,000
Closed -$176K
CHRS icon
157
Coherus Oncology
CHRS
$217M
– –
-258,716
Closed -$7.48M
CNMD icon
158
CONMED
CNMD
$1.3B
– –
-8,554
Closed -$498K
CYH icon
159
Community Health Systems
CYH
$382M
– –
-4,813
Closed -$250K
DHR icon
160
Danaher
DHR
$138B
– –
-14,878
Closed -$856K
ENTA icon
161
Enanta Pharmaceuticals
ENTA
$362M
– –
-4,956
Closed -$223K
ESPR
162
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-200,000
Closed -$16.4M
LKFT
163
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-20,000
Closed -$1.03M
HRTX icon
164
Heron Therapeutics
HRTX
$93.4M
– –
-448,000
Closed -$14M
ILMN icon
165
Illumina
ILMN
$29.5B
– –
-25,700
Closed -$5.46M
IMUX icon
166
PUT
Immunic
IMUX
$178M
– –
-750
Closed -$6.33M
INCY icon
167
Incyte
INCY
$25.4B
– –
-15,000
Closed -$1.56M
INSM icon
168
Insmed
INSM
$22.4B
– –
-285,812
Closed -$6.98M
LMAT icon
169
LeMaitre Vascular
LMAT
$2.37B
– –
-19,838
Closed -$239K
MCK icon
170
McKesson
MCK
$104B
– –
-1,015
Closed -$228K
MCRB icon
171
Seres Therapeutics
MCRB
$45M
– –
-2,500
Closed -$2.08M
MGNX icon
172
MacroGenics
MGNX
$233M
– –
-76,208
Closed -$2.89M
NKTR icon
173
Nektar Therapeutics
NKTR
$2.39B
– –
-22,333
Closed -$4.19M
PAHC icon
174
Phibro Animal Health
PAHC
$1.5B
– –
-6,809
Closed -$265K
PBYI icon
175
CALL
Puma Biotechnology
PBYI
$398M
– –
-100,000
Closed -$11.7M
5 6
7
8 9

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q3 2015 filing shows 40 new, 31 increased, 43 reduced and 54 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M. The largest sale was ZS PHARMA INC COMS TK (DE), an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.